Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $40.1 million.

  • Ironwood Pharmaceuticals' Net Income towards Common Stockholders rose 999.29% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 156.81%. This contributed to the annual value of $102.8 million for FY2024, which is 108.17% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Net Income towards Common Stockholders of $40.1 million as of Q3 2025, which was up 69.84% from $23.6 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Income towards Common Stockholders peaked at $391.3 million during Q2 2021, and registered a low of -$1.1 billion during Q2 2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $3.6 million (2024), whereas its average is -$102.6 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first slumped by 3,038.30% in 2023, then soared by 2,844.07% in 2025.
  • Ironwood Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $41.4 million in 2021, then climbed by 18.16% to $48.9 million in 2022, then tumbled by 567.15% to -$228.3 million in 2023, then soared by 145.63% to $104.2 million in 2024, then soared by 999.29% to $40.1 million in 2025.
  • Its Net Income towards Common Stockholders was $40.1 million in Q3 2025, compared to $23.6 million in Q2 2025 and -$37.4 million in Q1 2025.